Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy

被引:13
作者
Yoshida, Kazuhiko [1 ]
Takagi, Toshio [1 ]
Kondo, Tsunenori [2 ]
Kobayashi, Hirohito [1 ]
Iizuka, Junpei [1 ]
Fukuda, Hironori [1 ]
Ishihara, Hiroki [1 ]
Okumi, Masayoshi [1 ]
Ishida, Hideki [1 ]
Tanabe, Kazunari [1 ]
机构
[1] Tokyo Womens Univ Hosp, Dept Urol, Tokyo, Japan
[2] Tokyo Womens Med Univ, Dept Urol, Med Ctr East, Tokyo, Japan
关键词
metastatic renal cell carcinoma; tyrosine kinase inhibitor; axitinib; immune checkpoint inhibitor; nivolumab; GROWTH-FACTOR RECEPTOR; SELECTIVE INHIBITOR; RESPONSE RATES; OPEN-LABEL; CHEMOTHERAPY; BLOCKADE; CANCER;
D O I
10.1093/jjco/hyz040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We reviewed the clinical efficacy of axitinib after nivolumab treatment failure in six patients with metastatic renal cell carcinoma (RCC); the patients had received nivolumab treatment following vascular endothelial growth factor receptor (VEGFR) inhibitors. Most had undergone radical nephrectomy; five had clear-cell carcinoma and acquired cystic disease-associated carcinoma. The patients were finally diagnosed with progressive disease during nivolumab treatment. Immediately after nivolumab treatment failure, one patient receiving pazopanib had an adverse event soon after, and subsequently received axitinib, which the others received. The size of the metastatic tumors treated with axitinib after nivolumab was on average 33.9% smaller. Following treatment, three patients experienced partial response with remarkable tumor shrinkage and three had stable disease (SD), of which most maintained for >5 months. One patient with SD died from gradual tumor progression after axitinib treatment. Axitinib treatment after nivolumab treatment failure can be beneficial for some patients with metastatic RCC.
引用
收藏
页码:576 / 580
页数:5
相关论文
共 50 条
[41]   Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma [J].
Ueda, Kosuke ;
Suekane, Shigetaka ;
Hirano, Taishi ;
Ogasawara, Naoyuki ;
Chikui, Katsuaki ;
Uemura, Keiichiro ;
Nakiri, Makoto ;
Nishihara, Kiyoaki ;
Matsuo, Mitsunori ;
Igawa, Tsukasa .
ANTICANCER RESEARCH, 2018, 38 (09) :5387-5392
[42]   The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma [J].
Kameda, Tomohiro ;
Takayama, Tatsuya ;
Sugihara, Toru ;
Takeshima, Saki ;
Yamazaki, Masahiro ;
Komatsubara, Maiko ;
Kamei, Jun ;
Fujisaki, Akira ;
Ando, Satoshi ;
Kurokawa, Shinsuke ;
Fujimura, Tetsuya .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) :241-246
[43]   Axitinib in metastatic renal cell carcinoma: single center experience [J].
Buraczewska, Agnieszka ;
Kardas, Joanna .
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (06) :481-485
[44]   Axitinib Controlled Metastatic Renal Cell Carcinoma for 5 Years [J].
Takayama, Tatsuya ;
Nagata, Masao ;
Kai, Fumitake ;
Sugiyama, Takayuki ;
Ozono, Seiichiro .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (07) :747-751
[45]   Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma [J].
Ishikawa, Gaku ;
Sugiyama, Takayuki ;
Ito, Toshiki ;
Otsuka, Atsushi ;
Miyake, Hideaki .
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2021, 10 (02) :116-118
[46]   Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma [J].
Gaku Ishikawa ;
Takayuki Sugiyama ;
Toshiki Ito ;
Atsushi Otsuka ;
Hideaki Miyake .
International Cancer Conference Journal, 2021, 10 :116-118
[47]   Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study [J].
Iinuma, Koji ;
Kameyama, Koji ;
Kawada, Kei ;
Fujimoto, Shota ;
Takagi, Kimiaki ;
Nagai, Shingo ;
Ito, Hiroki ;
Ishida, Takashi ;
Kawase, Makoto ;
Kawase, Kota ;
Nakai, Chie ;
Kato, Daiki ;
Takai, Manabu ;
Nakane, Keita ;
Koie, Takuya .
CURRENT ONCOLOGY, 2021, 28 (02) :1402-1411
[48]   Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma [J].
Okada, Takuro ;
Matsuki, Takashi ;
Fushimi, Chihiro ;
Okamoto, Isaku ;
Sato, Hiroki ;
Kondo, Takahito ;
Tokashiki, Kunihiko ;
Ito, Tatsuya ;
Masubuchi, Tatsuo ;
Tada, Yuichiro ;
Miura, Kouki ;
Hanyu, Kenji ;
Omura, Go ;
Takahashi, Hideki ;
Yamashita, Taku ;
Oridate, Nobuhiko ;
Tsukahara, Kiyoaki .
ANTICANCER RESEARCH, 2022, 42 (10) :4907-4912
[49]   Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma [J].
Ishiyama, Yudai ;
Kondo, Tsunenori ;
Tachibana, Hidekazu ;
Ishihara, Hiroki ;
Fukuda, Hironori ;
Yoshida, Kazuhiko ;
Takagi, Toshio ;
Iizuka, Junpei ;
Tanabe, Kazunari .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) :552-561
[50]   Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma [J].
Numakura, Kazuyuki ;
Sekine, Yuya ;
Hatakeyama, Shingo ;
Muto, Yumina ;
Sobu, Ryuta ;
Kobayashi, Mizuki ;
Sasagawa, Hajime ;
Kashima, Soki ;
Yamamto, Ryohei ;
Nara, Taketoshi ;
Akashi, Hideo ;
Tabata, Ryuji ;
Sato, Satoshi ;
Saito, Mitsuru ;
Narita, Shintaro ;
Ohyama, Chikara ;
Habuchi, Tomonori .
CANCER MEDICINE, 2023, 12 (16) :16837-16845